Sequus Amphotec empiric data insufficient to prove equal efficacy to amphotericin B -- advisory cmte.
EMPIRIC ANTIFUNGAL COMPOSITE SAFETY/EFFICACY ENDPOINTS SHOULD BE AVOIDED in future trials of systemic antifungals, FDA's Antiviral Advisory Committee recommended at an April 14 meeting. Sequus presented a composite of efficacy and safety endpoints in support of Amphotec's (amphotericin B cholesteryl sulfate complex) efficacy as an empirical treatment for systemic fungal infections.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth